{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T04:42:25Z","timestamp":1776746545930,"version":"3.51.2"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"DOI":"10.1186\/s12913-026-14337-0","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T02:33:13Z","timestamp":1773369193000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The patient\u2019s voice: real-world experiences of a transthyretin amyloidosis focus group"],"prefix":"10.1186","volume":"26","author":[{"given":"M\u00f3nica Ang\u00e9lica","family":"L\u00f3pez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom\u00e1s","family":"Ripoll-Vera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Sevilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prado","family":"Salamanca-Bautista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inmaculada","family":"Mediavilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Francisco","family":"Soto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"CARABELA-ATTR Scientific Committee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"issue":"3","key":"14337_CR1","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/joim.13169","volume":"289","author":"E Muchtar","year":"2020","unstructured":"Muchtar E, Dispenzieri A, Magen H, et al. Systemic amyloidosis from A (AA) to T (ATTR): a review. J Intern Med. 2020;289(3):268\u201392.","journal-title":"J Intern Med"},{"issue":"2","key":"14337_CR2","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40120-018-0106-z","volume":"7","author":"M Stewart","year":"2018","unstructured":"Stewart M, Shaffer S, Murphy B, et al. Characterizing the High Disease Burden of Transthyretin Amyloidosis for Patients and Caregivers. Neurol Ther. 2018;7(2):349\u201364.","journal-title":"Neurol Ther"},{"issue":"2","key":"14337_CR3","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/mus.26515","volume":"60","author":"A Yarlas","year":"2019","unstructured":"Yarlas A, Gertz MA, Dasgupta NR, et al. Burden of hereditary transthyretin amyloidosis on quality of life. Muscle Nerve. 2019;60(2):169\u201375.","journal-title":"Muscle Nerve"},{"issue":"1","key":"14337_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","volume":"140","author":"T Lane","year":"2019","unstructured":"Lane T, Fontana M, Martinez-Naharro A, et al. Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis. Circulation. 2019;140(1):16\u201326.","journal-title":"Circulation"},{"issue":"5","key":"14337_CR5","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.regg.2020.05.001","volume":"55","author":"S Yun","year":"2020","unstructured":"Yun S, Gonz\u00e1lez-Costello J, Formiga F. Amiloidosis por transtiretina: lo que ahora vemos es solo la punta del iceberg. Rev Esp Geriatr Gerontol. 2020;55(5):255\u20137.","journal-title":"Rev Esp Geriatr Gerontol"},{"issue":"1","key":"14337_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jama.2020.5493","volume":"324","author":"MA Gertz","year":"2020","unstructured":"Gertz MA, Dispenzieri A. Systemic Amyloidosis Recognition, Prognosis, and Therapy. JAMA. 2020;324(1):79.","journal-title":"JAMA"},{"issue":"1","key":"14337_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1750-1172-9-29","volume":"9","author":"JB Rein\u00e9s","year":"2014","unstructured":"Rein\u00e9s JB, Vera TR, Mart\u00edn MU, et al. Epidemiology of transthyretin-associated familial amyloid polyneuropathy in the Majorcan area: Son Ll\u00e0tzer Hospital descriptive study. Orphanet J Rare Dis. 2014;9(1):29.","journal-title":"Orphanet J Rare Dis"},{"issue":"19","key":"14337_CR8","doi-asserted-by":"publisher","first-page":"e2036","DOI":"10.1212\/WNL.0000000000207158","volume":"100","author":"S Zampino","year":"2023","unstructured":"Zampino S, Sheikh FH, Vaishnav J, et al. Phenotypes Associated With the Val122Ile, Leu58His, and Late-Onset Val30Met Variants in Patients With Hereditary Transthyretin Amyloidosis. Neurology. 2023;100(19):e2036\u201344.","journal-title":"Neurology"},{"issue":"6","key":"14337_CR9","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.rec.2021.07.020","volume":"75","author":"J \u00c1lvarez Rubio","year":"2022","unstructured":"\u00c1lvarez Rubio J, Manovel S\u00e1nchez AJ, Gonz\u00e1lez-Costello J, et al. Characterization of hereditary transthyretin cardiac amyloidosis in Spain. Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition). 2022;75(6):488\u201395.","journal-title":"Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"},{"issue":"2","key":"14337_CR10","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s40120-021-00267-y","volume":"10","author":"J Gonz\u00e1lez-Moreno","year":"2021","unstructured":"Gonz\u00e1lez-Moreno J, Losada-L\u00f3pez I, Cisneros-Barroso E, et al. A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey. Neurol Ther. 2021;10(2):833\u201345.","journal-title":"Neurol Ther"},{"issue":"2","key":"14337_CR11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/13506129.2022.2142110","volume":"30","author":"F de Frutos","year":"2023","unstructured":"de Frutos F, Ochoa JP, G\u00f3mez-Gonz\u00e1lez C, et al. Phenotype and clinical outcomes of Glu89Lys hereditary transthyretin amyloidosis: a new endemic variant in Spain. Amyloid. 2023;30(2):199\u2013207.","journal-title":"Amyloid"},{"issue":"22","key":"14337_CR12","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg FL, Grogan M, Hanna M, et al. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73(22):2872\u201391.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"14337_CR13","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/s13023-023-02962-5","volume":"18","author":"L Gentile","year":"2023","unstructured":"Gentile L, Coelho T, Dispenzieri A, et al. A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS). Orphanet J Rare Dis. 2023;18(1):350.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"14337_CR14","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/s10741-021-10080-2","volume":"27","author":"JN Nativi-Nicolau","year":"2022","unstructured":"Nativi-Nicolau JN, Karam C, Khella S, et al. Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness. Heart Fail Rev. 2022;27(3):785\u201393.","journal-title":"Heart Fail Rev"},{"issue":"1","key":"14337_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s40119-023-00344-3","volume":"13","author":"J Gonz\u00e1lez-Moreno","year":"2024","unstructured":"Gonz\u00e1lez-Moreno J, Dispenzieri A, Grogan M, et al. Clinical and Genotype Characteristics and Symptom Migration in Patients With Mixed Phenotype Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey. Cardiol Ther. 2024;13(1):117\u201335.","journal-title":"Cardiol Ther"},{"issue":"5","key":"14337_CR16","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/eurheartj\/ehz173","volume":"43","author":"T Damy","year":"2022","unstructured":"Damy T, Kristen AV, Suhr OB, et al. Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS). Eur Heart J. 2022;43(5):391\u2013400.","journal-title":"Eur Heart J"},{"issue":"8","key":"14337_CR17","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","volume":"7","author":"RM Witteles","year":"2019","unstructured":"Witteles RM, Bokhari S, Damy T, et al. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. JACC Heart Fail. 2019;7(8):709\u201316.","journal-title":"JACC Heart Fail"},{"key":"14337_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejim.2020.09.025","volume":"82","author":"A Porcari","year":"2020","unstructured":"Porcari A, Merlo M, Rapezzi C, et al. Transthyretin amyloid cardiomyopathy: An uncharted territory awaiting discovery. Eur J Intern Med. 2020;82:7\u201315.","journal-title":"Eur J Intern Med"},{"issue":"8","key":"14337_CR19","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3109\/07853890.2015.1068949","volume":"47","author":"PN Hawkins","year":"2015","unstructured":"Hawkins PN, Ando Y, Dispenzeri A, et al. Evolving landscape in the management of transthyretin amyloidosis. Ann Med. 2015;47(8):625\u201338.","journal-title":"Ann Med"},{"key":"14337_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1750-1172-9-61","volume":"9","author":"J Wixner","year":"2014","unstructured":"Wixner J, Mundayat R, Karayal ON, et al. THAOS: gastrointestinal manifestations of transthyretin amyloidosis - common complications of a rare disease. Orphanet J Rare Dis. 2014;9:61.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"14337_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s41687-020-00273-y","volume":"5","author":"A Lovley","year":"2021","unstructured":"Lovley A, Raymond K, Guthrie SD, et al. Patient-reported burden of hereditary transthyretin amyloidosis on functioning and well-being. J Patient Rep Outcomes. 2021;5(1):3.","journal-title":"J Patient Rep Outcomes"},{"issue":"1","key":"14337_CR22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40120-020-00183-7","volume":"9","author":"A Gonz\u00e1lez-Duarte","year":"2020","unstructured":"Gonz\u00e1lez-Duarte A, Concei\u00e7\u00e3o I, Amass L, et al. Impact of Non-Cardiac Clinicopathologic Characteristics on Survival in Transthyretin Amyloid Polyneuropathy. Neurol Ther. 2020;9(1):135\u201349.","journal-title":"Neurol Ther"},{"issue":"Suppl 2","key":"14337_CR23","doi-asserted-by":"publisher","first-page":"e178","DOI":"10.2459\/JCM.0000000000001424","volume":"24","author":"C Autore","year":"2023","unstructured":"Autore C, Bariani R, Bauce B, et al. From the phenotype to precision medicine: an update on the cardiomyopathies diagnostic workflow. J Cardiovasc Med (Hagerstown). 2023;24(Suppl 2):e178\u201386.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"14337_CR24","doi-asserted-by":"publisher","unstructured":"Briasoulis A, Bampatsias D, Papamichail A, et al. Invasive and non-invasive diagnostic pathways in the diagnosis of cardiac amyloidosis. J Cardiovasc Dev Dis. 2023;10. https:\/\/doi.org\/10.3390\/jcdd10060256.","DOI":"10.3390\/jcdd10060256"},{"key":"14337_CR25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2147\/TCRM.S219979","volume":"16","author":"M Luigetti","year":"2020","unstructured":"Luigetti M, Romano A, Di Paolantonio A, et al. Diagnosis and Treatment of Hereditary Transthyretin Amyloidosis (hATTR) Polyneuropathy: Current Perspectives on Improving Patient Care. Ther Clin Risk Manag. 2020;16:109\u201323.","journal-title":"Ther Clin Risk Manag"},{"key":"14337_CR26","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/S0735-1097(19)31471-8","volume":"73","author":"A Sikora Kessler","year":"2019","unstructured":"Sikora Kessler A, Yarlas A, Lovley A, CLINICAL OUTCOME ASSESSMENT SCORES FOR PATIENTS WITH TRANSTHYRETIN AMYLOIDOSIS WITH OR WITHOUT ACCOMPANYING CARDIOMYOPATHY OR CONGESTIVE HEART FAILURE, et al. J Am Coll Cardiol. 2019;73:864.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"14337_CR27","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13023-020-1340-x","volume":"15","author":"M In\u00eas","year":"2020","unstructured":"In\u00eas M, Coelho T, Concei\u00e7\u00e3o I, et al. Health-related quality of life in hereditary transthyretin amyloidosis polyneuropathy: a prospective, observational study. Orphanet J Rare Dis. 2020;15(1):67\u201367.","journal-title":"Orphanet J Rare Dis"},{"key":"14337_CR28","doi-asserted-by":"crossref","unstructured":"Escalada J, Carretero Gomez J, Anguita M, et al. Enhancing the management of chronic diseases in clinical practice: The CARABELA methodology. J Healthc Qual Res. 2024.","DOI":"10.1016\/j.jhqr.2024.06.001"},{"issue":"5","key":"14337_CR29","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1002\/ehf2.12793","volume":"7","author":"D Dang","year":"2020","unstructured":"Dang D, Fournier P, Cariou E, et al. Gateway and journey of patients with cardiac amyloidosis. ESC Heart Fail. 2020;7(5):2418\u201330.","journal-title":"ESC Heart Fail"},{"key":"14337_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.hjc.2023.05.004","volume":"73","author":"EA Apostolou","year":"2023","unstructured":"Apostolou EA, Fontrier AM, Efthimiadis GK, et al. The patient pathway in ATTR-CM in Greece and how to improve it: A multidisciplinary perspective. Hellenic J Cardiol. 2023;73:73\u201380.","journal-title":"Hellenic J Cardiol"},{"key":"14337_CR31","doi-asserted-by":"publisher","first-page":"1238843","DOI":"10.3389\/fcvm.2023.1238843","volume":"10","author":"L Ponti","year":"2023","unstructured":"Ponti L, Hsu K, Damy T, et al. Burden of untreated transthyretin amyloid cardiomyopathy on patients and their caregivers by disease severity: results from a multicenter, non-interventional, real-world study. Front Cardiovasc Med. 2023;10:1238843.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"14337_CR32","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13023-021-01706-7","volume":"16","author":"D Rintell","year":"2021","unstructured":"Rintell D, Heath D, Braga Mendendez F, et al. Patient and family experience with transthyretin amyloid cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN) amyloidosis: results of two focus groups. Orphanet J Rare Dis. 2021;16(1):70.","journal-title":"Orphanet J Rare Dis"},{"issue":"1, Supplement","key":"14337_CR33","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/j.acvd.2023.10.067","volume":"117","author":"S Oghina","year":"2024","unstructured":"Oghina S, Legallois D, Fournier P, et al. Evaluating the current physicians\u2019 knowledge and patients\u2019 pathways for diagnosing transthyretin cardiac amyloidosis (ATTR-CM) in France: An extensive survey of diverse medical specialists. Arch Cardiovasc Dis. 2024;117(1, Supplement):S38.","journal-title":"Arch Cardiovasc Dis"},{"key":"14337_CR34","doi-asserted-by":"publisher","first-page":"175394472312163","DOI":"10.1177\/17539447231216318","volume":"17","author":"CS Kwok","year":"2023","unstructured":"Kwok CS, Moody WE. The importance of pathways to facilitate early diagnosis and treatment of patients with cardiac amyloidosis. Ther Adv Cardiovasc Dis. 2023;17:17539447231216318.","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"9","key":"14337_CR35","doi-asserted-by":"publisher","first-page":"e073130","DOI":"10.1136\/bmjopen-2023-073130","volume":"13","author":"L Obici","year":"2023","unstructured":"Obici L, Callaghan R, Ablett J, et al. Consensus recommendations on holistic care in hereditary ATTR amyloidosis: an international Delphi survey of patient advocates and multidisciplinary healthcare professionals. BMJ Open. 2023;13(9):e073130.","journal-title":"BMJ Open"},{"issue":"2","key":"14337_CR36","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s40119-021-00222-w","volume":"10","author":"H Koike","year":"2021","unstructured":"Koike H, Okumura T, Murohara T, et al. Multidisciplinary Approaches for Transthyretin Amyloidosis. Cardiol Ther. 2021;10(2):289\u2013311.","journal-title":"Cardiol Ther"},{"issue":"10","key":"14337_CR37","doi-asserted-by":"publisher","first-page":"e13296","DOI":"10.1111\/eci.13296","volume":"50","author":"I Losada","year":"2020","unstructured":"Losada I, Gonz\u00e1lez-Moreno J, Rodriguez A, et al. Multidisciplinary approach in the management of hATTR. Eur J Clin Invest. 2020;50(10):e13296.","journal-title":"Eur J Clin Invest"},{"key":"14337_CR38","doi-asserted-by":"publisher","first-page":"117954682110152","DOI":"10.1177\/11795468211015230","volume":"15","author":"J Nativi-Nicolau","year":"2021","unstructured":"Nativi-Nicolau J, Sarswat N, Fajardo J, et al. Best Practices in Specialized Amyloidosis Centers in the United States: A Survey of Cardiologists, Nurses, Patients, and Patient Advocates. Clin Med Insights Cardiol. 2021;15:11795468211015230.","journal-title":"Clin Med Insights Cardiol"},{"issue":"1","key":"14337_CR39","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40119-021-00219-5","volume":"10","author":"MH Rozenbaum","year":"2021","unstructured":"Rozenbaum MH, Large S, Bhambri R, et al. Impact of Delayed Diagnosis and Misdiagnosis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): A Targeted Literature Review. Cardiol Ther. 2021;10(1):141\u201359.","journal-title":"Cardiol Ther"},{"issue":"1","key":"14337_CR40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1185\/03007995.2012.754348","volume":"29","author":"T Coelho","year":"2013","unstructured":"Coelho T, Maurer MS, Suhr OB. THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin. 2013;29(1):63\u201376.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"14337_CR41","doi-asserted-by":"publisher","first-page":"3","DOI":"10.14797\/mdcj-8-3-3","volume":"8","author":"KR Baker","year":"2012","unstructured":"Baker KR, Rice L. The amyloidoses: clinical features, diagnosis and treatment. Methodist Debakey Cardiovasc J. 2012;8(3):3\u20137.","journal-title":"Methodist Debakey Cardiovasc J"},{"issue":"3","key":"14337_CR42","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1080\/13506129.2018.1498782","volume":"25","author":"E Bishop","year":"2018","unstructured":"Bishop E, Brown EE, Fajardo J, et al. Seven factors predict a delayed diagnosis of cardiac amyloidosis. Amyloid. 2018;25(3):174\u20139.","journal-title":"Amyloid"},{"issue":"9","key":"14337_CR43","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1080\/00015385.2021.1976450","volume":"77","author":"P Debonnaire","year":"2022","unstructured":"Debonnaire P, Claeys M, De Smet M, et al. Trends in diagnosis, referral, red flag onset, patient profiles and natural outcome of de novo cardiac amyloidosis and their multidisciplinary implications. Acta Cardiol. 2022;77(9):791\u2013804.","journal-title":"Acta Cardiol"},{"issue":"6","key":"14337_CR44","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2217\/nmt-2019-0020","volume":"9","author":"VE Thomas","year":"2019","unstructured":"Thomas VE, Smith J, Benson MD, et al. Amyloidosis: diagnosis and new therapies for a misunderstood and misdiagnosed disease. Neurodegener Dis Manag. 2019;9(6):289\u201399.","journal-title":"Neurodegener Dis Manag"},{"key":"14337_CR45","doi-asserted-by":"crossref","unstructured":"Bampatsias D, Wardhere A, Maurer MS. Treatment of transthyretin cardiac amyloidosis. Curr Opin Cardiol. 2024.","DOI":"10.1097\/HCO.0000000000001156"},{"issue":"1","key":"14337_CR46","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL, et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018;379(1):22\u201331.","journal-title":"N Engl J Med"},{"issue":"17","key":"14337_CR47","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","volume":"389","author":"MS Maurer","year":"2023","unstructured":"Maurer MS, Kale P, Fontana M, et al. Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis. N Engl J Med. 2023;389(17):1553\u201365.","journal-title":"N Engl J Med"},{"issue":"11","key":"14337_CR48","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018;379(11):1007\u201316.","journal-title":"N Engl J Med"},{"issue":"1","key":"14337_CR49","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13023-024-03052-w","volume":"19","author":"SM Ihne-Schubert","year":"2024","unstructured":"Ihne-Schubert SM, Radovic T, Fries S, et al. Needs of amyloidosis patients and their care providers: design & first results of the AMY-NEEDS research and care program. Orphanet J Rare Dis. 2024;19(1):58.","journal-title":"Orphanet J Rare Dis"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-026-14337-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14337-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14337-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T04:12:54Z","timestamp":1776744774000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12913-026-14337-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["14337"],"URL":"https:\/\/doi.org\/10.1186\/s12913-026-14337-0","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"12 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients recruited for this initiative provided informed consent to participate and authorized the processing of their personal data (e-mail address, age, sex, geographical origin, medical condition, years since diagnosis) and their responses to the questionnaire provided during the session. The data collection process was conducted in full compliance with the current Spanish legislation on personal data protection, specifically Organic Law 3\/2018, of December 5, on the Protection of Personal Data and Guarantee of Digital Rights (\n                      \n                      ). This study consisted of qualitative interviews with ATTR patients developed for this study, without involving clinical interventions or the collection of sensitive health data. According to Spanish research regulations, including Law 14\/2007 of July 3 on Biomedical Research and Royal Decree 1090\/2015 of December 4, which primarily govern research involving clinical interventions or medicinal products, ethical committee approval was not required for this type of study. All procedures were conducted following the principles outlined in the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"In the last three years, the following conflicts of interest have been disclosed: LG has received research grants from Alnylam, consulting fees from Alnylam, AstraZeneca and Pfizer, speaker fees and travel\/congress assistance from Alnylam and Pfizer, and equipment\/materials support from Pfizer; MAL has received speaker\/lecturer honoraria from Alnylam, Pfizer and Takeda, meeting attendance\/travel support from Takeda, and honoraria for participation in data safety monitoring\/advisory boards; TR-V has received consulting fees from Alnylam and Pfizer, and honoraria for participation in lectures\/presentations from AstraZeneca; IM declares no conflict of interest; JFS has received research grants from Alnylam, consulting fees from Alnylam, AstraZeneca and Pfizer, speaker fees and travel\/congress assistance from Alnylam and Pfizer, and equipment\/materials support from Pfizer.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"559"}}